The European Medicines Agency (EMA) has qualified PathAI’s AIM-MASH AI Assist as the first artificial intelligence tool to support the identification of inflammatory liver disease in biopsy samples for the enrollment of patients in clinical trials and the assessment of primary and secondary endpoints.
European Medicine Agency’s CHMP Qualifies First AI Tool For Use In Clinical Trials
PathAI’s Tool Can Increase Reproducibility And Repeatability
With the support of AIM-MASH AI Assist only one pathologist is needed to reliably make a histology assessment of inflammatory liver disease to decide whether patients should be included in MASH clinical trials.
